ANO1 and cystic fibrosis: Recent work has proposed activation or potentiation of Ca2+ activated TMEM16A (anoctamin 1) chloride ion channels as a mutation-agnostic treatment for people with cystic fibrosis (CF) and other inflammatory airway diseases [1].